Singular Research Reiterates Buy-Venture Rating for FSD Pharma (NASDAQ:HUGE)

FSD Pharma (NASDAQ:HUGE)‘s stock had its “buy-venture” rating reaffirmed by investment analysts at Singular Research in a research report issued to clients and investors on Tuesday, Zacks.com reports. Singular Research also issued estimates for FSD Pharma’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.12) EPS.

FSD Pharma Trading Down 4.3 %

NASDAQ:HUGE opened at $0.35 on Tuesday. FSD Pharma has a 12-month low of $0.34 and a 12-month high of $1.68. The stock’s 50 day simple moving average is $0.63 and its 200-day simple moving average is $0.86. The firm has a market cap of $13.97 million, a P/E ratio of -0.74 and a beta of 0.71.

FSD Pharma (NASDAQ:HUGE) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.04) earnings per share (EPS) for the quarter.

Institutional Trading of FSD Pharma

An institutional investor recently raised its position in FSD Pharma stock. AdvisorShares Investments LLC increased its position in shares of FSD Pharma Inc. (NASDAQ:HUGE) by 14.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 270,316 shares of the company’s stock after purchasing an additional 34,679 shares during the quarter. AdvisorShares Investments LLC owned 0.69% of FSD Pharma worth $249,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.24% of the company’s stock.

About FSD Pharma

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.